Completed NA INTERVENTIONAL NCT00217880

Significance of Biological Markers in Patients With Acute Lung Injury/Acute Respiratory Disease

Prognostic Significance of Biological Markers in Patients With ALI/ARDS

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Respiratory Distress Syndrome, Adult

Updated 5 times since 2017 Last updated: Aug 16, 2013 Started: Jul 31, 2004 Primary completion: Apr 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00217880, this NA trial focuses on Respiratory Distress Syndrome, Adult and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)
University of Michigan

Data source: University of Michigan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ann Arbor, United States
• Atlanta, United States